Kinases have emerged as one of the most intensively pursued targets in current pharmacological 2 research, especially for cancer, due to their critical roles in cellular signaling. To date, the USA 3 Food and Drug Administration (FDA) has approved twenty-eight small molecule kinase inhibitors, 4 half of which were approved in the past three years. While the clinical data of these approved 5 molecules are widely presented and structure-activity relationship (SAR) has been reported for 6 individual molecules, an updated review that analyzes all approved molecules and summarizes 7 current achievements and trends in the field has yet to be found. Herein we present all approved 8 small molecule kinase inhibitors with an emphasis on binding mechanism and structural features, 9 summarize current challenges, and discuss future directions in this field. 10 11 Keywords: 12 cancer, protein kinase, lipid kinase, tyrosine kinase, serine/threonine kinase, crystal structure 13
Kinase inhibitors: A burgeoning field
The past one and half decades witnessed an unparalleled success in the development of 2 therapeutically useful kinase inhibitors, powered by tremendous progress in both academic and 3 industrial settings. The milestone approval of the first kinase inhibitor, imatinib, in 2001 by FDA, 4 was followed by a slow, yet steady approval of kinase inhibitors in the first ten years of this 5 century with almost one new approval per year on average. Concurrently, our understanding of 6 kinase signaling networks and disease pathology steadily grew, culminating in the approval of 7 fifteen new small molecule kinase inhibitors from January 2012 to February 2015 -an unparalleled 8 achievement in the history of pharmaceutical research. As of March 2015, a total of twenty-eight 9 small molecule kinase inhibitors have been approved along with a large number of other 10 compounds currently being evaluated in clinical and preclinical trials. In addition, more than one 11 million publications on kinases have been released, more than five thousand crystal structures of 12 kinases with or without small molecules have been solved, inhibition assays have been developed 13 for more than four-fifths of the human kinome, and small molecule kinase inhibitors have been 14 identified for about one-fifth of the human kinome. All these facts reflect the surging interest in 15 this field. Thus, it is now safe to state that the development of small molecule kinase inhibitors has 16 emerged as one of the most extensively pursued areas of drug discovery. In spite the abundance 17 of data, common binding modes and structural features of approved small molecule kinase 18 inhibitors are rarely reported in a systematic way that is easily accessible. Instead, information on 19 individual inhibitors and their analogues appears scattered and fragmented. In this review, we 20 provide a comprehensive overview and discuss the function mechanism and structural binding 21 features of approved small molecule kinase inhibitors based on co-crystal structures. With the 22 notion that fifteen kinase inhibitors were approved by FDA in the short period from 2012 to 23 4 February 2015, emphasis will be put on those small molecules, for which few SAR discussions have 1 been presented. The intention of this review is to compile structural and binding information 2 useful for the discovery of new kinase inhibitors, summarize current limitations and challenges, [2]. Accumulating pharmacological and pathological evidence have revealed that kinases are 10 promising drug targets for the treatment of numerous diseases [3] , such as cancers [4] [5] [6] , 11 inflammatory diseases [7, 8] , central nervous system (CNS) disorders [9] , cardiovascular diseases 12 [10] , and complications of diabetes [11] . 13 Pioneering studies on the characterization of the phosphorylase kinase in the 1950s [12] [13] [14] , and 14 the identification of the first kinase signaling cascade involving protein kinase A (PKA) in 1968 [15] , 15 constituted the first few pieces of the jigsaw puzzle of kinase cascades. The "decade of protein 16 kinase cascades" in 1990s witnessed the unfolding of the mitogen-activated protein 17 kinases/extracellular signal-regulated kinases (MARK/ERK, also known as Ras-Raf-MEK-ERK) 18 pathway, the Janus kinases (JAK) pathway, and the phosphoinositide 3-kinase (PI3K) pathway [16, 19 17]. So far, 518 human kinases and more than 900 genes encoding proteins with kinase activity 20 have been confirmed [18, 19] . Albeit accounting for only about 5% of the total number of protein- X-ray crystallography [29, 30] . 10 Among the 28 clinically approved kinase inhibitors, most are tyrosine kinase inhibitors [31], few 11 are serine/threonine kinase inhibitors, and one, idelalisib, is a lipid kinase inhibitor that was 12 approved in Jul., 2014 ( Figure 2 ). Judged by different binding modes, 26 are reversible inhibitors, 13 and the remaining two, afatinib and ibrutinib, are irreversible inhibitors. Despite several promising 14 allosteric kinase inhibitors being currently in clinical trials at different stages, trametinib is the only 15 type III inhibitor approved so far. In this review, approved small molecule kinase inhibitors are 16 discussed and grouped into different classes based on their binding modes and targets.
17

Approved tyrosine kinase inhibitors 18
Reversible non-receptor tyrosine kinase (NRTK) inhibitors 19 BCR-Abl was the first kinase for which a small molecule inhibitor was successfully approved [32] . 20 On another note, being the first approved kinase inhibitor and a revolutionary success for the 21 7 treatment of chronic myeloid leukemia (CML) [17] , imatinib has been the subject of various SAR 1 studies to guide the design of next-generation inhibitors and provide a deeper understanding of 2 the inhibition mechanism. Considerable efforts seek to develop inhibitors based on structural 3 features derived from imatinib and its binding mode with BCR-Abl [33, 34] . Five BCR-Abl inhibitors 4 have been approved so far: imatinib (Gleevec®, Novartis), dasatinib (Sprycel®, Squibbs), nilotinib (Tasigna®, Novartis), Bosutinib (Bosulif®, Wyeth), and Ponatinib (Iclusig®, Ariad [36, 37] . Thus, nilotinib was developed as a second-line therapy for CML that is imatinib-18 resistant due to point mutations on BCR-Abl, including E255V, M351T, and F486S. Nilotinib shares 19 the same pyridine-pyrimidine-aminotolyl moiety with imatinib, the difference being the long chain 20 binding within the allosteric pocket. The imidazole-phenyl moiety and the attached 21 trifluoromethyl group make it possible for nilotinib to bind deeper and tighter within the allosteric 22 pocket ( Figure 3C and 3D). Nilotinib is potent against most mutations but not the common 23 8 gatekeeper mutation T315I which blocks the binding into the allosteric pocket due to mutation of 1 the small threonine residue to a bulky isoleucine residue. In this context, ponatinib was developed 2 as a new BCR-Abl inhibitor that exhibits potent T315I inhibitory activity. Instead of having a 3 pyrimidineamino linker interacting with the gatekeeper residue Thr315, a slim alkyne linker that 4 overcomes steric hindrance due to mutation of the gate-keeper residue was incorporated in 5 ponatinib. Besides, ponatinib bears the piperizinylphenyl group of imatinib and the trifluoromethyl 6 group of nilotinib, resulting in a more compact interaction with the allosteric pocket ( Figure 3E Structures of EGFR kinases with mutations at L858R or T790M have also been solved by several 20 different groups. Extensive efforts to crystalize drug-resistant double mutant L858R+T790M EGFR 21 failed to give diffraction-quality crystals, until a structure of EGFR with L858R+T790M+V948R 22 mutations was recently co-crystalized with gefitinib [52] ( Figure 6C ). In contrast to the wild type 1 EGFR conformation that showed an active state with Leu858 buried in the kinase N-lobe, this 2 mutant EGFR structure adopted an inactive-like state where Arg858 residue is exposed to the 3 solvent front. Although gefitinib, erlotinib and vandetanib are the few inhibitors for which no 4 experimental evidence regarding inactive state recognition has been collected so far, this gefitinib-5 mutant EGFR co-crystal structure showed that maybe there is no structural hindrance for these 6 inhibitors to bind with the inactive form of EGFR. SAR and structural features obtained from these 7 mutant kinase complexes provide a new dimension for the development of kinase inhibitors that 8 may better address challenging issues regarding selectivity and drug-resistance. Due to the high 9 structural similarity, the erlotinib-EGFR complex showed the same binding mode with that of 10 gefitinib-EGFR complex, albeit with different 6,7-quinazoline substituents exposed in the solvent interacts with a small part of the allosteric pocket through its terminal benzamide group, and 1 nintedanib binds with the allosteric pocket using its terminal methylcarboxy group. Another 2 difference among these four compounds is the presence of a solubilizing chain: both sunitinib and 3 nintedanib have a long terminal chain lying in the solvent region, axitinib's moderate-length 4 pyridylvinyl chain extends to the solvent front, while sorafenib is basically buried inside the 5 binding pocket without direct interaction with the solvent. In the case of nintedanib, ionic 6 interactions are formed between the N-methylpiperazinyl group and Glu850. Regorafenib only 7 differs from sorafenib by the presence of a fluorine atom ( Figure 7I ), thus similar type II binding 8 with VEGFR2 as for sorafenib is expected. Both sorafenib and regorafenib are multi-target protein 9 kinase inhibitors. Besides inhibition of VEGFR and B-raf, sorafenib has also been shown to be a 10 potent low nanomolar inhibitor of p38α through binding with its inactive conformation (3GCS, 2.1 11 Å) [62] . A predicted type II binding mode of pazopanib with VEGFR2 is depicted ( Figure 7J including the two approved molecules: above-mentioned crizotinib and the dual MET and VEGFR2 10 inhibitor cabozantinib (Cometriq®, Exelixis). A recent study showed that cabozantinib overcomes 11 crizotinib resistance stemming from acquired mutations in ROS1 [75] . 12 MET-crizotinib complex showed a type I binding mode similar to that of the ALK-crizotinib 13 complex with the DFG adopting an "in" conformation [68] ( Figure 9A ). The hinge hydrogen bonds 14 involving the aminopyridine core are preserved, while the 3-fluoro-2,6-dichlorobenzyl moiety 15 binds in a big hydrophilic pocket adjacent to the solvent front ( Figure 9B, 9C) . In spite of the 16 absence of a MET co-crystal structure with cabozantinib ( Figure 9D) , the MET complex with 17 compound DWF ( Figure 9E ), a closely related analogue, showed a potent type II binding mode. The Figure 10F ). In the case of ibrutinib, the cyclopentyl group is replaced with an N-acryloylpiperidine 8 group that acts as a Michael acceptor in reaction with the vicinal cysteine. Vemurafenib ( Figure 11A ) was developed using a fragment-based drug discovery strategy. The 20 V600E B-Raf-vemurafenib co-crystal structure showed a type I binding mode. Vemurafenib 21 occupies the ATP binding site with a DFG-in conformation, enabling the formation of hydrogen 22 bond interactions between the sulfonamide moiety and the DFG residues. Hydrogen bonds are 1 also formed between the pyrrolopyridine core and hinge residue Cys532 and Gln530, mimicking 2 that of the adenine core of ATP. The terminal 4-chlorophenyl group is exposed to the solvent front. 3 Besides, an outward shift of the regulatory αC-helix caused by vemurafenib binding to the kinase 4 was observed [83] (Figure 11B, 11C) . Although no co-crystal structure of dabrafenib ( Figure 11D (Figure 11G-11I) . 19 Along the MAPK pathway, MEK is another target for which a considerable number of small 20 molecule inhibitors have been identified [85] , including the only approved molecule trametinib 21 (Mekinist®, GlaxoSmithKline) ( Figure 12A ). Trametinib was developed based on a high-throughput 22 screening hit that bears the same pyridopyrimidinetrione core. SAR studies driven by growth 23 19 inhibitory activity against cancer cell lines lead to the discovery of trametinib [86], whose target 1 was then confirmed as MEK1 and MEK2 guided by the structural features of known MEK inhibitors. 2 The co-crystal structure of MEK1 with an analogue of trametinib, TAK-733 ( Figure 12B Kinase-based drug discovery has achieved dramatic progress in the past fifteen years. Although 20 kinase inhibition stands for a young therapeutic strategy in comparison with other traditional 21 tactics targeting G-protein-coupled receptors (GPCRs), membrane channels and transporters, 22 protease, etc., an analysis of FDA-approved cancer drugs since 1980s reveals that kinases have 1 already taken over from G-protein-coupled receptor (GPCR) as the most sought-after cellular 2 targets for cancer treatment [108] . Our analysis of all FDA-approved molecule kinase inhibitors 3 with a focus on binding mechanism and structural features reveals some general conclusions that 4 form the current landscape of developing kinase inhibitors and reflects a number of significant 5 challenges in spite of achieved advances. 6 First, only a small subset of the human kinome has been studied. Most kinase inhibition efforts 7 are limited to a select group of kinases that belong to the tyrosine kinase (TK) group, although 8 promising results are emerging for inhibition of kinases in groups of tyrosine-kinase like (TKL), 9 containing CDK, MAPK, GSK3 and CLK kinases (CMGC), containing PKA, PKG and PKC kinases (AGC), 10 and containing the calcium/calmodulin-dependent protein kinases (CAMK) in recent years. This 11 imbalance is clearly illustrated by the fact that inhibitors of three groups of tyrosine kinases, BCR-12 Abl, ErbBs, VEGFRs, account for eighteen of the twenty-seven approved protein kinase inhibitors. 13 Second, in contrast with protein kinase inhibitors, only one lipid kinase inhibitor is currently on 14 the market. Even though lipid kinase inhibitors were reported as early as 1990s and a variety of 15 clinical and pre-clinical lipid kinase inhibitors have been published [102], few have showed 16 sufficient activity used in single-agent trials. 17 Third, despite the fact that kinases signaling cascade regulates diverse cellular activities related 18 to inflammatory indications, CNS disorders, cardiovascular disease, diabetes, and others, in 19 addition to cancer, most currently available inhibitors, including 26 out of the 28 approved kinase 20 inhibitors, are developed mainly for cancer treatment. 21 Fourth, many of the current kinase inhibitors were designed based on previously approved 22 compounds, as shown by the high structural similarity among approved ErbB inhibitors, e.g., five 23 23 ErbB inhibitors share the same 4-(arylamino)quinazoline core with different 6-and/or 7-1 substituents. Consequently, only a small subset of chemotypes are being investigated, which is 2 clearly reflected by the limited number of moieties that are being incorporated in the approved 3 molecules. 4 Fifth, most inhibitors function as reversible inhibitors binding in the ATP binding pocket and due 5 to the high sequence similarity around the ATP binding pockets of kinases, it has been a daunting 6 task to develop kinase inhibitors with potent inhibition against desirable targets and minimal 7 interactions with off-targets. 8 Sixth, closely connected with the previous point, a large number of inhibitors interact with more 9 than one target. In contrast, few absolute-selective inhibitors, which might be evaluated as dual or 10 multiple target inhibitors if a more comprehensive screening assay was used [109], have been 11 identified so far.
12
Future directions
13 Based on the current trends discussed above, some challenging questions that might serve as 14 directions for future development of small molecule kinase inhibitors and push the boundary of 15 the research in this field need to be addressed appropriately. 16 First, the fact that current kinase inhibitors focus only on a small subset of the human kinome 17 indicates that many kinases are neglected. Thus, there is a need to develop tools and selective 18 probes to uncover the functions of these unknown kinases [110] , which might serve as new 19 targets for small molecule inhibitors. It is encouraging to see the approval of a first inhibitor 20 targeting certain kinases in the past three years, like trametinib as the first approved MEK inhibitor 21 in 2013, ibrutinib as the first approved BTK inhibitor in 2013, and palbociclib as the first approved 22 CDK inhibitor in 2015. 23 24 Second, although significant efforts have been devoted to the development of lipid kinase 1 inhibitors, the progress achieved is not as obvious as for protein kinase inhibitors. The approval of 2 the first and only lipid kinase inhibitor idelalisib in 2014 added support to the strategy of using 3 lipid kinase inhibitors as anticancer agents, especially in combination with other cancer treatment 4 agents and methods. Considering the pivotal roles of lipids kinases, such as PI3Ks, in cellular 5 cascade, it is reasonable to expect research on small molecule lipid kinase inhibitors for indications 6 including not only cancer but also inflammation, to be a promising direction in this field. 7 Third, except being utilized in the prevalent theme for cancer treatment, kinase inhibitors have 8 great potential in the treatment of nonlethal chronic diseases, such as cardiovascular and CNS 9 disorders. The successful approval of tofacitinib established the concept for the treatment of 10 arthritis. Even for cancer treatment, more knowledge needs to be gained to further understand 11 the multifaceted cancer biology. 12 Fourth, more pharmacophores need to be explored to diversify the scaffolds of kinase inhibitors. 13 Most currently approved kinase inhibitors are discovered based on hits from high-throughput 14 screening (HTS), while HTS is becoming increasingly less effective since most useful scaffolds have 15 already been retrieved from available compound libraries. So there is an urgent need to diversify 16 the molecules in compound library for screening. Natural products, which usually contain 17 pharmacophores and scaffolds that are different from most synthetic kinase inhibitors, could be a 18 useful source to inspire the construction of libraries with expanded structural diversity. 19 Fifth, despite the fact that most approved kinase inhibitors are type I and II reversible inhibitors, 20 the success of afatinib and ibrutinib stand as strong stimulators to rekindle the idea of targeting 21 kinases with irreversible inhibitors. On the other hand, type III and IV inhibitors might show 22 different efficacy and selectivity in comparison with type I and II inhibitors. In a word, novel 1 mechanism of action needs to be explored. 2 Sixth, the selectivity issue of kinase inhibitors has always been a controversial area. Early 3 promiscuous inhibitors, e.g. staurosporine, and later pan-selective inhibitors have functioned as 4 useful tools in oncology. Highly selective kinase inhibitors were actively sought after until the 5 recent theory that inhibitors with favorable selectivity or multi-target selectivity might be more 6 suitable for cancer treatment becoming more and more widely accepted. It has become clear that 7 kinase inhibitors do not have to be absolute-selective, a favorable selectivity profile is needed to 8 balance efficacy and toxicity. 
